Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal

Both Bristol-Myers and Celgene face separate challenges, and some Wall Street analysts questioned whether the combination - which the companies said would create $2.5 billion in cost savings and significantly raise earnings - would solve them.

from Moneycontrol Business News http://bit.ly/2R8qRNX